What is the recommended peri‑operative management for a patient with type 1 von Willebrand disease?

Perioperative Management of Type 1 von Willebrand Disease

For patients with type 1 VWD undergoing surgery, desmopressin (DDAVP) 0.3 μg/kg is the first-line treatment, with VWF/FVIII concentrates reserved for non-responders or when desmopressin is inadequate. 1

First-Line Treatment: Desmopressin

Desmopressin should be administered at 0.3 μg/kg diluted in 50 mL saline and infused over 30 minutes for patients with type 1 VWD presenting for surgery 1. This synthetic vasopressin analog stimulates endogenous VWF release from endothelial stores, binding platelets to collagen through GP1b receptors and to other platelets through GPIIb/IIIa receptors 1.

Pre-surgical DDAVP Testing

• Perform a desmopressin challenge test before elective procedures to confirm adequate response, defined as 1-hour VWF Activity/Factor VIII ≥0.50 IU/mL 2
• DDAVP-responsiveness varies significantly (53-92% depending on definition used), making pre-procedural testing essential 2
• Consider patient bleeding history beyond DDAVP response: patients with bleeding scores >15 may require additional hemostatic support even if DDAVP-responsive 2

When DDAVP is Adequate

• For minor procedures: DDAVP ± tranexamic acid (TXA) provides adequate hemostatic coverage in most type 1 VWD patients 1, 2
• For major procedures: DDAVP combined with TXA is effective in 86.7% of cases when patients are appropriately selected 2
• Preoperative administration of DDAVP is useful for patients with VWD undergoing cardiac surgery 1

Second-Line Treatment: VWF/FVIII Concentrates

When desmopressin response is inadequate or contraindicated, specific VWF/FVIII concentrates are indicated 1. The American Society of Anesthesiologists guidelines specifically state that bleeding patients with type 1 VWD should be treated with desmopressin first, then VWF/FVIII concentrate if there is no response or availability 1.

Target Levels for Surgery

• Maintain VWF and FVIII levels at minimum 50 IU/dL for neuraxial anesthesia and major surgical procedures 1, 3
• Target levels should be maintained for 3-5 days for minor procedures and 7-14 days for major surgery until bleeding risk abates 4
• For emergency surgery, coadminister VWF and FVIII to ensure immediate hemostasis 4
• For elective procedures, early VWF infusion stabilizes endogenous FVIII, reducing need for exogenous FVIII 4

Monitoring Considerations

• Frequent monitoring of plasma levels is essential during major surgery, as repeated VWF supplementation (particularly with plasma-derived FVIII-containing products) may lead to FVIII accumulation 4
• Access to hemostatic testing is critical for patients with more severe forms of VWD undergoing major procedures 4

Adjunctive Therapy: Tranexamic Acid

Tranexamic acid should be combined with desmopressin or VWF concentrates for enhanced hemostatic efficacy 1, 3. TXA is inexpensive, widely available, and effective as an adjunct across bleeding disorders, with hemostatic efficacy >90% when combined with DDAVP in small series 1.

Alternative if VWF Concentrates Unavailable

If VWF/FVIII concentrate is not available and desmopressin fails, cryoprecipitate should be administered 1. Each unit of cryoprecipitate contains VWF and fibrinogen, though specific concentrates are strongly preferred when available 1.

Critical Pitfalls to Avoid

• Do not use prophylactic DDAVP in patients without documented VWD or platelet hemostatic defects: meta-analyses show no benefit in cardiac surgery patients without bleeding disorders 1
• Avoid assuming all type 1 VWD patients respond to DDAVP: 10-47% may have inadequate responses requiring concentrate therapy 2
• Do not neglect bleeding history assessment: baseline bleeding scores help identify patients at higher risk of post-surgical bleeding who may need more aggressive prophylaxis 4
• Monitor for FVIII accumulation: repeated dosing with plasma-derived VWF/FVIII concentrates can cause supraphysiologic FVIII levels and potential thrombotic risk 4